Illumina Reports Q1 2026 Earnings with Revenue Growth and Strong Demand for NovaSeq X Systems
Illumina (ILMN) reported Q1 2026 earnings with total revenue of $1.09 billion, up 4.8% year-over-year, driven by instrument sales and clinical consumables demand. The company saw strong growth in sequencing consumables and NovaSeq X placements, with 82% of sequencing volumes on the NovaSeq X systems.
Tickers: $ILMN
Topics: Clinical Consumables Earnings Report NovaSeq X Revenue Growth Sequencing Instruments